Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice-Reference-Cited by-同舟云学术

Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice

Published:2005-11 Issue:11 Volume:23 Page:2071-2082
ISSN:0263-6352
Container-title:Journal of Hypertension
language:en
Short-container-title:

Author:

Jandeleit-Dahm Karin,Lassila Markus,Davis Belinda J,Candido Riccardo,Johnston Colin I,Allen Terri J,Burrell Louise M,Cooper Mark E

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Reference31 articles.

1. Optimizing treatment of hypertension in patients with diabetes;Cooper;JAMA,2000

2. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction;Haffner;N Engl J Med,1998

3. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes;Tikkanen;J Hypertens,2002

4. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats;Cao;Kidney Int,2001

5. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy;Davis;Diabetologia,2003

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease;Frontiers in Physiology;2020-06-03

2. Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db / db diabetic mice;Physiological Reports;2020-02

3. Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes;Diabetes, Obesity and Metabolism;2018-01-17

4. Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications?;Biomedicine & Pharmacotherapy;2017-06

5. The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications;Trends in Endocrinology & Metabolism;2015-10